Finnlines collaborates and interacts with different stakeholders and organisations. One of the organisations is the Aamu Pediatric Cancer Foundation which Finnlines supported in 2017. This year Finnlines has, as before, continued cooperation with the cycling charity Team Rynkeby – God Morgon as the Finnish teams cross over to Travemünde onboard Finnlines to begin their journey to Paris.
Cooperation with Nordic charity cycling team
Approximately 300 cyclist and service team members from seven different cities in Finland started their journey towards Paris from Helsinki, Vuosaari in June 2018, to raise funds for children with cancer. The Finnish teams cross over to Travemünde onboard Finnlines.
Every summer Team Rynkeby – God Morgon Finland cycle to Paris to raise money for seriously ill children in Denmark, Sweden, Finland, Norway and Germany. In each country the money is donated to local organisations that help children. In 2018, Team Rynkeby donated to the Finnish organisations a record amount of EUR 886,372.
The next Rynkeby trip to Paris is already on the upswing. Around 2,100 cyclists across 54 teams in seven countries are expected to cycle to Paris with the charity cycling Team Rynkeby. Finnlines will be a part of the journey for the Finnish teams.
Aid to children
During 2017, Finnlines was an official Finland 100 partner and supported the Aamu Pediatric Cancer Foundation with EUR 50,000.
Aamu Pediatric Cancer Foundation supports implementation of newest research achievements for the treatment of children and adolescents diagnosed with cancer. Liver tumours are rare but severe and account for 1% of paediatric tumours. Their incidence, however, has been increasing with improved neonatal care for preterm infants, who have an increased risk of developing liver tumours.
Finland has just been asked to join the Paediatric Hepatic International Tumour Trial (PHITT) that is a clinical trial within the Children’s Liver Tumour European Research Network (ChiLTERN) Programme. Due to Finnlines’ donation to the implementation of the PHITT Trial in Finland via Aamu we have now the possibility to be part of the most advantageous liver treatment for children.